June 2nd 2025
Two implants have recently been performed in Israel
Paris, June 2, 2025 – 7 am CEST
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces the first implants of its Aeson® artificial heart in a commercial set-up, outside the European Union (EU).
Two implants of Aeson® artificial heart were performed during the week commencing May 26, 2025 in Israel.
The first one was carried out at Hadassah Ein Kerem Hospital in Jerusalem by a team led by Pr Offer Amir, Pr Rabea Asleh and Dr Amit Korach, respectively director of the Heart Institute, director of heart failure unit and director of the cardiac surgery department at Hadassah Medical Center.
The second one was carried out at Sheba Medical Center in Ramat Gan (Tel Aviv), by a team led by Dr Jeff Morgan, Dr Leonid Sternik, Dr Alex Fardman and Dr Eyal Nachum, respectively head of mechanical support unit, director of cardiac surgery department, heart failure cardiologist and cardiac transplant surgeon.
Those are the first Aeson® implants made in a commercial set-up outside the European Union.
These implants bring to 5 the total number of countries[1] where commercial implants have been performed so far. They confirm the trust placed in the device by healthcare professionals, and the growing interest in the therapy.
[1] Germany, Italy, Spain, Poland and Israel.